Identification

Name
Ceftriaxone
Accession Number
DB01212
Description

Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic.1 It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges1, eyes9, and inner ear6. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.1

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 554.58
Monoisotopic: 554.04605704
Chemical Formula
C18H18N8O7S3
Synonyms
  • Ceftriaxona
  • Ceftriaxone
  • Ceftriaxonum
  • Rocephin
External IDs
  • DRG-0071
  • Ro 139904

Pharmacology

Indication

Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms.11 Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.1

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms.11 Ceftriaxone has in vitro activity against gram-positive aerobic, gram-negative aerobic, and anaerobic bacteria.12 The bactericidal activity of ceftriaxone results from the inhibition of cell wall synthesis and is mediated through ceftriaxone binding to penicillin-binding proteins (PBPs).10 Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended-spectrum beta-lactamases.11 However, resistance to ceftriaxone usually occurs through beta-lactamase hydrolysis, altered PBPs, or reduced bacterial cell permeability.10 Ceftriaxone should not be mixed with or giving in the same IV line as diluents/products containing calcium as they may cause ceftriaxone to precipitate.11 Ceftriaxone use may also cause biliary sludge or gallbladder pseudolithiasis.11,2

Mechanism of action

Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall.10,11 The beta-lactam moiety of ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. Binding of ceftriaxone to these enzymes causes the enzyme to lose activity; therefore, the bacteria produce defective cell walls, causing cell death.

TargetActionsOrganism
APenicillin-binding protein 2B
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
USolute carrier family 22 member 11Not AvailableHumans
USolute carrier family 22 member 6Not AvailableHumans
USolute carrier family 22 member 8Not AvailableHumans
USolute carrier family 15 member 1Not AvailableHumans
Absorption

Ceftriaxone is only given as an injection, either intramuscularly or intravenously.11 Ceftriaxone is less than 1% bioavailable if given orally.3

Volume of distribution

The apparent volume of distribution of an intravenous or intramuscular dose in healthy patients is 5.78 to 13.5 L.11 The volume of distribution of an intravenous or intramuscular dose in septic patients is 6.48 to 35.2 L.4 Ceftriaxone has good enough CSF penetration to be used as an effective treatment of bacterial meningitis.5

Protein binding

Ceftriaxone is 95% protein bound.11

Metabolism

Metabolism of ceftriaxone is negligible.

Route of elimination

Ceftriaxone is primarily eliminated in the urine (33-67%).11 The remainder is eliminated through secretion in the bile and removed from the body via the feces.

Half-life

The elimination half-life of ceftriaxone is 5.8-8.7 hours.11 The half-life of ceftriaxone in the middle ear fluid has been estimated to be 25 hours.11,6

Clearance

The plasma clearance of ceftriaxone in healthy adults receiving a 0.15-3g dose is 0.58 to 1.45 L/hour.11 The renal clearance of ceftriaxone is 0.32 to 0.73 L/hour.11 In intensive care unit patients, ceftriaxone's total drug clearance was 0.96L/h (0.55-1.28 L/h), and unbound drug clearance was 1.91 L/h (1.46-6.20 L/h).7

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Ceftriaxone overdose may increase the risk of urolithiasis and subsequent post-renal acute renal failure (PARF).8 Other symptoms of overdose unavailable in the literature. However, they are likely similar to the adverse effects of the medication. If overdose of ceftriaxone occurs, treat with symptomatic and supportive treatment, as ceftriaxone levels will not be reduced by dialysis.11

Affected organisms
  • Enteric bacteria and other eubacteria
  • Neisseria meningitidis
  • Haemophilus influenzae
  • Neisseria gonorrhoeae
  • Escherichia coli
  • Salmonella typhi
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirCeftriaxone may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftriaxone.
AcarboseCeftriaxone may decrease the excretion rate of Acarbose which could result in a higher serum level.
AceclofenacCeftriaxone may decrease the excretion rate of Aceclofenac which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Ceftriaxone which could result in a higher serum level.
AcenocoumarolThe risk or severity of bleeding can be increased when Ceftriaxone is combined with Acenocoumarol.
AcetaminophenCeftriaxone may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Ceftriaxone which could result in a higher serum level.
AclidiniumCeftriaxone may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Product Ingredients
IngredientUNIICASInChI Key
Ceftriaxone sodium023Z5BR09K104376-79-6PMRZKYOXTPBIQF-MAODNAKNSA-J
International/Other Brands
Acantex (Roche) / Biotrakson (Bioton) / Rocephine (Roche)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Ceftriaxone and DextroseInjection, solution2 g/50mLIntravenousB. Braun Medical Inc.2005-04-20Not applicableUS flag
Ceftriaxone and DextroseInjection, solution1 g/50mLIntravenousB. Braun Medical Inc.2005-04-20Not applicableUS flag
Ceftriaxone for InjectionPowder, for solutionIntramuscular; IntravenousFresenius KabiNot applicableNot applicableCanada flag
Ceftriaxone for InjectionPowder, for solutionIntramuscular; IntravenousFresenius KabiNot applicableNot applicableCanada flag
Ceftriaxone for InjectionPowder, for solutionIntramuscular; IntravenousFresenius KabiNot applicableNot applicableCanada flag
Ceftriaxone for InjectionPowder, for solutionIntramuscular; IntravenousFresenius KabiNot applicableNot applicableCanada flag
Ceftriaxone for InjectionPowder, for solutionIntramuscular; IntravenousFresenius KabiNot applicableNot applicableCanada flag
Ceftriaxone for InjectionPowder, for solutionIntravenousFresenius Kabi2014-06-05Not applicableCanada flag
Ceftriaxone for Injection USPPowder, for solutionIntramuscular; IntravenousPfizer Canada Ulc2007-11-302019-06-28Canada flag
Ceftriaxone for Injection USPPowder, for solutionIntramuscular; IntravenousPfizer Canada Ulc2007-11-302019-06-28Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CeftriaxoneInjection, powder, for solution500 mg/1Intramuscular; IntravenousLupin Pharmaceuticals, Inc.2009-06-01Not applicableUS flag
CeftriaxonePowder, for solution250 mg/1Intramuscular; IntravenousHikma Farmaceutica2008-01-102008-01-10US flag
CeftriaxoneInjection, powder, for solution250 mg/1Intramuscular; IntravenousA-S Medication Solutions2005-08-022017-10-31US flag
CeftriaxoneInjection, powder, for solution500 mg/1Intramuscular; IntravenousRebel Distributors2007-04-12Not applicableUS flag
CeftriaxoneInjection, solution1 g/50mLIntravenousBaxter Healthcare Corporation2005-08-23Not applicableUS flag
CeftriaxoneInjection, powder, for solution250 mg/1IntramuscularRemedy Repack2014-06-022017-02-28US flag
CeftriaxoneInjection, powder, for solution10 g/1IntravenousLupin Pharmaceuticals, Inc.2006-09-122018-01-25US flag
CeftriaxoneInjection, powder, for solution100 mg/1mLIntravenousApotex Corporation2005-08-022017-07-31US flag
CeftriaxoneInjection, powder, for solution500 mg/1Intramuscular; IntravenousBedford Pharmaceuticals2009-07-222014-12-31US flag
CeftriaxoneInjection, powder, for solution2 g/1Intramuscular; IntravenousAurobindo Pharma2008-07-312012-01-31US flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
J01DD04 — CeftriaxoneJ01DD54 — Ceftriaxone, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporins
Alternative Parents
N-acyl-alpha amino acids and derivatives / 2,4-disubstituted thiazoles / Alkylarylthioethers / 1,2,4-triazines / 1,3-thiazines / 2-amino-1,3-thiazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids
show 12 more
Substituents
1,2,4-triazine / 1,3-thiazol-2-amine / 2,4-disubstituted 1,3-thiazole / Alkylarylthioether / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl thioether
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin, 1,3-thiazole, oxime O-ether, 1,2,4-triazines (CHEBI:29007) / Cephems (C06683)

Chemical Identifiers

UNII
75J73V1629
CAS number
73384-59-5
InChI Key
VAAUVRVFOQPIGI-SPQHTLEESA-N
InChI
InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1
IUPAC Name
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][[email protected]]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[[email protected]]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

References

Synthesis Reference

Monguzzi Riccardo, Menaspace Silvano, Anzaghi Piergiorgio, "Process for the preparation of ceftriaxone." U.S. Patent US5026843, issued November, 1984.

US5026843
General References
  1. Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS: Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984 Jun;27(6):469-527. doi: 10.2165/00003495-198427060-00001. [PubMed:6329638]
  2. Park HZ, Lee SP, Schy AL: Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991 Jun;100(6):1665-70. doi: 10.1016/0016-5085(91)90667-a. [PubMed:2019372]
  3. Lee S, Kim SK, Lee DY, Chae SY, Byun Y: Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats. Antimicrob Agents Chemother. 2006 May;50(5):1869-71. doi: 10.1128/AAC.50.5.1869-1871.2006. [PubMed:16641464]
  4. Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, Perrotin D, Dequin PF, Le Guellec C: Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol. 2011 Nov;72(5):758-67. doi: 10.1111/j.1365-2125.2011.04005.x. [PubMed:21545483]
  5. Rockowitz J, Tunkel AR: Bacterial meningitis. Practical guidelines for management. Drugs. 1995 Nov;50(5):838-53. doi: 10.2165/00003495-199550050-00005. [PubMed:8586029]
  6. Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson KG: Penetration of ceftriaxone into the middle ear fluid of children. Pediatr Infect Dis J. 1998 Mar;17(3):258-60. doi: 10.1097/00006454-199803000-00022. [PubMed:9535262]
  7. Schleibinger M, Steinbach CL, Topper C, Kratzer A, Liebchen U, Kees F, Salzberger B, Kees MG: Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol. 2015 Sep;80(3):525-33. doi: 10.1111/bcp.12636. Epub 2015 Jun 11. [PubMed:25808018]
  8. Shen-Hua W, Fan-Yi M, Qing-Ling Z, Li-Na Z, Li-Jun M: Ceftriaxone-associated renal toxicity in adults: a case report and recommendations for the management of such cases. J Clin Pharm Ther. 2016 Jun;41(3):348-350. doi: 10.1111/jcpt.12358. Epub 2016 Feb 23. [PubMed:26913690]
  9. Gobeaux D, Ambart L, Couderc JL, Renard PH, De Charnace B, Lokiec F: Ceftriaxone diffusion from blood to aqueous humour in man. Br J Ophthalmol. 1989 Jul;73(7):574-5. doi: 10.1136/bjo.73.7.574. [PubMed:2758000]
  10. Sivapalasingam S., Steigbigel N. (2015). Mandell, Douglas and Bennett's Principles and practice of infectious diseases (8th ed.). Elsevier.
  11. DailyMed Label: ceftriaxone sodium injection, powder for solution [Link]
  12. FDA: Ceftriaxone - Injection products [Link]
Human Metabolome Database
HMDB0015343
KEGG Drug
D07659
KEGG Compound
C06683
PubChem Compound
5479530
PubChem Substance
46506458
ChemSpider
4586394
BindingDB
50103601
RxNav
2193
ChEBI
29007
ChEMBL
CHEMBL161
ZINC
ZINC000028467879
Therapeutic Targets Database
DAP000145
PharmGKB
PA448866
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ceftriaxone
AHFS Codes
  • 08:12.06.12 — Third Generation Cephalosporins
FDA label
Download (211 KB)
MSDS
Download (53.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedHealth Services ResearchMeningitis / Neurological Infections1
4CompletedPreventionCalcium Nephrolithiasis / Urinary Tract Infection1
4CompletedPreventionEsophageal and Gastric Varices / Gastrointestinal Hemorrhage1
4CompletedPreventionPneumonia1
4CompletedTreatmentAbscess, Intra-Abdominal / Appendicitis / Diverticulitis / Gallbladder Inflammation / Intra-Abdominal Infections / Peritonitis1
4CompletedTreatmentAcute Uncomplicated Pyelonephritis1
4CompletedTreatmentAppendicitis / Cross Infection / Diverticulitis / Gallbladder Inflammation / Peritonitis1
4CompletedTreatmentCommunity Acquired Pneumonia (CAP)2
4CompletedTreatmentComplicated Appendicitis1
4CompletedTreatmentComplicated Intra-Abdominal Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • American Regent
  • Apotex Inc.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bedford Labs
  • Biopharma SRL
  • Cardinal Health
  • Cephazone Pharma LLC
  • Cura Pharmaceutical Co. Inc.
  • Dispensing Solutions
  • F Hoffmann La Roche Ltd.
  • F Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Inc.
  • Hanmi Fine Chemical Co. Ltd.
  • Hikma Pharmaceuticals
  • Hospira Inc.
  • Lupin Pharmaceuticals Inc.
  • Medisca Inc.
  • Orchid Healthcare
  • Patheon Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Rebel Distributors Corp.
  • Sagent Pharmaceuticals
  • Sandoz
  • Teva Pharmaceutical Industries Ltd.
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Parenteral1 G/3.5ML
Injection, powder, for solutionIntramuscular; Parenteral500 MG/2ML
Injection, powder, for solutionIntravenous; Parenteral1 G/10ML
Powder, for solution2 G
Injection, powder, for solutionIntravenous1 g
Injection, powder, for solutionIntramuscular1.106 g
Injection, powder, for solutionIntramuscular0.5 g
Injection, powder, for solutionIntravenous0.5 g
Injection, powder, for solutionIntravenous; Parenteral1000 MG/10ML
Injection, powder, for solutionIntramuscular1 gr
Injection, powder, for solutionIntramuscular250 mg
Injection, powder, for solutionIntravenous1 gr
Injection, powder, for solutionIntravenous250 mg
Injection, powder, for solutionIntravenous500 mg
Injection, solutionIntramuscular; Intravenous0.5 g
Injection, solutionIntramuscular; Intravenous1 g
InjectionIntravenous2 g
Injection
Injection, powder, for solutionIntramuscular2 gr
Injection, powder, for solutionIntravenous2 gr
Injection, powder, for solutionParenteral1 g
Injection, powder, for solutionIntravenous1.184 g
Injection, powder, for solutionIntramuscular; Intravenous1000 mg
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g
Injection, powder, for solutionIntramuscular1 g/1
Injection, powder, for solutionIntramuscular250 mg/1
Injection, powder, for solutionIntramuscular; Intravenous1 g/10mL
Injection, powder, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, for solutionIntramuscular; Intravenous250 mg/1
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, for solutionIntravenous10 g/100mL
Injection, powder, for solutionIntravenous10 g/1
Injection, powder, for solutionIntravenous100 mg/1mL
Injection, powder, for solutionIntravenous100 g/1
Injection, powder, for solutionIntravenous2 g/1
Injection, powder, lyophilized, for solutionIntravenous100 mg/1mL
Powder, for solutionIntramuscular; Intravenous1 g/1
Powder, for solutionIntramuscular; Intravenous2 g/1
Powder, for solutionIntramuscular; Intravenous250 mg/1
Powder, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, for solutionIntramuscular; Parenteral250 MG/2ML
Injection, powder, for solutionIntravenous; Parenteral500 MG/5ML
Injection, powder, for solutionParenteral1 G/10ML
Injection, powder, for solutionIntramuscular; Parenteral250 MG
Injection, powder, for solutionIntramuscular; Parenteral500 MG
Powder, for solutionParenteral2 G
Injection, powder, for solutionIntramuscular1 G/3.5ML
Injection, powder, for solutionIntramuscular250 MG/2ML
Injection, powder, for solutionIntramuscular500 MG/2ML
Injection, powder, for solutionIntravenous1 G/10ML
SolutionIntravenous
Injection, powder, for solutionIntravenous; Parenteral1 G
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, for solutionIntravenous500 mg/1
Powder, for solutionIntramuscular; Intravenous
Powder, for solutionIntravenous
InjectionIntramuscular1000 mg
InjectionIntravenous1000 mg
InjectionIntramuscular500 mg
Injection, solutionIntramuscular0.5 g
InjectionIntravenous0.5 g
Injection, solutionIntramuscular1 g
InjectionIntravenous1 g
SolutionIntravenous2 g
Injection, powder, for solutionIntramuscular1 g
Injection, powder, for solutionIntramuscular; Intravenous1 g
Injection, powder, for solutionIntramuscular500 mg
Injection, solutionIntravenous0.5 g
Injection, solutionIntravenous1 g
Injection, powder, for solutionIntramuscular0.5 gr
Injection, powder, for solutionIntravenous0.5 gr
Injection, powder, for solutionIntravenous1000 mg
InjectionIntramuscular0.5 g/2ml
InjectionIntravenous0.5 g/5ml
InjectionIntravenous1 g/10ml
InjectionIntramuscular1 g/3.5ml
Powder2 G
Injection, powder, for solutionIntramuscular; Parenteral1 MG/3.5ML
Injection, powder, for solutionIntramuscular; Parenteral1 G
Injection, powder, for solutionIntravenous; Parenteral250 MG/5ML
Injection, solutionIntravenous1 g/50mL
Injection, solutionIntravenous2 g/50mL
Injection, solutionIntravenous2 g
Injection, solutionIntramuscular500 mg
Injection, solutionIntravenous1.0 g
InjectionIntramuscular; Intravenous1 gr
InjectionIntramuscular; Intravenous0.5 gr
Prices
Unit descriptionCostUnit
Rocephin 10 gm vial478.32USD vial
Rocephin 2 gm vial97.5USD vial
Ceftriaxone 2 gm piggyback94.17USD each
Rocephin 1 gm Solution Vial65.53USD vial
Rocephin 1 gm vial62.02USD vial
Ceftriaxone For Injection Usp 2 g/vial49.13USD vial
Ceftriaxone 1 gm piggyback47.91USD each
Rocephin 1 g/vial40.2USD vial
Ceftriaxone 10 gm vial36.25USD vial
Ceftriaxone 2 gm-d5w bag27.84USD each
Ceftriaxone For Injection Usp 1 g/vial24.93USD vial
Chloromycetin 1 g/vial20.33USD vial
Ceftriaxone 2 gm vial17.04USD vial
Ceftriaxone 1 gm-d5w bag13.92USD each
Rocephin 0.25 g/vial12.71USD vial
Ceftriaxone For Injection Usp 0.25 g/vial7.88USD vial
Ceftriaxone 1 gm vial7.56USD vial
Ceftriaxone sodium powder1.84USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)>155 °CNot Available
logP-1.7Not Available
Caco2 permeability-6.88ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.105 mg/mLALOGPS
logP-0.01ALOGPS
logP-1.9ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)2.7ChemAxon
pKa (Strongest Basic)3.36ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area208.98 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity128.47 m3·mol-1ChemAxon
Polarizability51.47 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.952
Blood Brain Barrier-0.9748
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.726
P-glycoprotein inhibitor INon-inhibitor0.8942
P-glycoprotein inhibitor IIInhibitor0.5293
Renal organic cation transporterNon-inhibitor0.8024
CYP450 2C9 substrateNon-substrate0.7943
CYP450 2D6 substrateNon-substrate0.8172
CYP450 3A4 substrateSubstrate0.5374
CYP450 1A2 substrateNon-inhibitor0.7538
CYP450 2C9 inhibitorNon-inhibitor0.7088
CYP450 2D6 inhibitorNon-inhibitor0.8666
CYP450 2C19 inhibitorNon-inhibitor0.7034
CYP450 3A4 inhibitorInhibitor0.6432
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5509
Ames testNon AMES toxic0.7336
CarcinogenicityNon-carcinogens0.8392
BiodegradationNot ready biodegradable0.9968
Rat acute toxicity2.1681 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9865
hERG inhibition (predictor II)Non-inhibitor0.6145
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Penicillin binding
Gene Name
penA
Uniprot ID
P0A3M6
Uniprot Name
Penicillin-binding protein 2B
Molecular Weight
73872.305 Da
References
  1. Tomberg J, Unemo M, Davies C, Nicholas RA: Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry. 2010 Sep 21;49(37):8062-70. doi: 10.1021/bi101167x. [PubMed:20704258]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Manganese ion binding
Specific Function
This enzyme has 2 functions: it catalyzes the production of glutamine and 4-aminobutanoate (gamma-aminobutyric acid, GABA), the latter in a pyridoxal phosphate-independent manner (By similarity). E...
Gene Name
GLUL
Uniprot ID
P15104
Uniprot Name
Glutamine synthetase
Molecular Weight
42064.15 Da
References
  1. Tumani H, Smirnov A, Barchfeld S, Olgemoller U, Maier K, Lange P, Bruck W, Nau R: Inhibition of glutamine synthetase in rabbit pneumococcal meningitis is associated with neuronal apoptosis in the dentate gyrus. Glia. 2000 Mar;30(1):11-8. [PubMed:10696140]
  2. Verma R, Mishra V, Sasmal D, Raghubir R: Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur J Pharmacol. 2010 Jul 25;638(1-3):65-71. doi: 10.1016/j.ejphar.2010.04.021. Epub 2010 Apr 24. [PubMed:20423712]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Other/unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Gulian JM, Dalmasso C, Gonard V: Interaction of beta-lactam antibiotics on bilirubin-albumin complex: comparison by three methods, total bilirubin, unbound bilirubin and erythrocyte-bound bilirubin. Chemotherapy. 1990;36(2):91-7. [PubMed:2311445]
  2. Nerli B, Farruggia B, Pico G: A comparative study of the binding characteristics of ceftriaxone, cefoperazone and cefsulodin to human serum albumin. Biochem Mol Biol Int. 1996 Nov;40(4):823-31. [PubMed:8950041]
  3. Robertson A, Fink S, Karp W: Effect of cephalosporins on bilirubin-albumin binding. J Pediatr. 1988 Feb;112(2):291-4. [PubMed:3339510]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
  2. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. [PubMed:12005172]
  3. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
  2. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. [PubMed:12005172]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Hanko E, Tommarello S, Watchko JF, Hansen TW: Administration of drugs known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brain. Pediatr Res. 2003 Oct;54(4):441-5. doi: 10.1203/01.PDR.0000085169.87948.B6. Epub 2003 Aug 6. [PubMed:12904601]

Drug created on June 13, 2005 07:24 / Updated on September 24, 2020 02:08

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates